Pluristem Requests Bloomberg Publish Corrections to Article

Pluristem Therapeutics

offered comments on an article published in Bloomberg on November 7, 2012. Pluristem has submitted a direct request to Bloomberg to publish a correction because the article it published is factually inaccurate and misleading. The subject of the article was a pediatric patient who was critically ill, in imminent danger of death and who had exhausted all other treatments. The patient was treated on a compassionate use basis in Israel, and was not part of Pluristem's ongoing clinical program. The patient was able to leave the hospital and survived six months, the last four of them in her home country of Romania. Pluristem was not monitoring the patient and learned of her death at the discretion of her family and physician. In addition, the formal report relating to the death clearly stated that there was no connection between the PLX cell treatment and the death of the patient. Pluristem has requested Bloomberg issue a correction specific to the article's claim and implication that Pluristem knew of the death of this patient at the time of a recent capital raising transaction and withheld this information from its